Treatment of redo-microvascular decompression or internal neurolysis plus microvascular decompression for recurrent trigeminal neuralgia: a review of long-term effectiveness and safety

J Int Med Res. 2022 Mar;50(3):3000605221080721. doi: 10.1177/03000605221080721.

Abstract

Objective: We examined the clinical characteristics and outcomes of patients with recurrent trigeminal neuralgia (TN) and assessed the long-term efficacy and safety of microvascular decompression (MVD) to treat typical recurrent TN.

Methods: We identified 3024 patients who underwent MVD for treatment of TN at the China-Japan Friendship Hospital from March 2009 to December 2020. We retrospectively analyzed the data and outcomes of 137 patients who underwent redo-MVD and 74 patients who did not undergo redo-MVD as the control group. These outcomes were evaluated using the Barrow Neurological Institute scoring system.

Results: Recurrence in 68 of the 137 patients was due to incomplete or absent decompression or new responsible vessels. To ensure thorough pain relief, redo-MVD should include decompression of both the trigeminal root entry zone and the peripheral nerve segments, where blood vessels can cause symptoms. Factors associated with reduced effectiveness of redo-MVD were no period of initial pain relief after the first MVD and a longer duration of symptoms before the first MVD.

Conclusions: Redo-MVD should not be excluded as a treatment option for patients with refractory TN who develop recurrent pain after a first MVD procedure.

Keywords: Recurrent trigeminal neuralgia; efficacy; long-term outcome; microvascular decompression; pain; safety; treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • Microvascular Decompression Surgery* / adverse effects
  • Postoperative Complications / etiology
  • Retrospective Studies
  • Treatment Outcome
  • Trigeminal Neuralgia* / complications
  • Trigeminal Neuralgia* / surgery